Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET

Company Participants

Carrie Mendivil - Investor Relations

Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director

Parag Mallick - Co-Founder, Chief Scientist & Director

Anna Mowry - Chief Financial Officer

Conference Call Participants

Yuko Oku - Morgan Stanley

Dave Delahunt - Goldman Sachs

Dan Brennan - Cowen

Operator

Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Carrie Mendivil Investor Relations.

Carrie Mendivil

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2023. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to investorrelations@nautilus.bio. Joining me today from Nautilus are: Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled "Forward-Looking Statements" in the press release of Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product, pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 2, 2023.

With that I'll turn the call over to Sujal.

Sujal Patel

Thanks, Carrie. Good morning, and thank you to everyone for joining us today. On this call we'll share our financial results for the second quarter and provide an update on our recent activities. But first, I want to take a moment to acknowledge the Nautilus teams in the Bay Area, Seattle and San Diego, who day in and day out exhibit the type of passion, ingenuity and commitment that will enable us to bring to market a platform that we believe will set the new gold standard for proteomic exploration. A platform capable of unleashing the potential of the proteome to advance basic science research, to build new diagnostics and of course, to make a substantial impact on drug development.